TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem M Solh, Uday Popat, Michele L. Donato, Luis Darío Piñeiro, Hugo Francisco Fernandez, Saar I. Gill, Anson Snow, Joseph P. Uberti
+7 more Timothy P. White, Yun Wang, Cuong Manh Nguyen, Chrystal Ursula Louis, Shrikanta Chattopadhyay, Michelle Elizabeth Matzko, Ran Reshef
DOI: 10.1016/j.jtct.2025.12.206
Cited by: 1

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Acute Myeloid Leukemia Research

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
2
Pages
S150–S151
Publication date
1 February 2026
Language
EN